EyePoint at Morgan Stanley conference: duravyu path stays open
At the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, EyePoint Pharmaceuticals (EYPT) shared both challenges and reasons for optimism regarding its lead wet age-related macular degeneration (AMD) program, DURAVYU. The company's intravitreal insert DURAVYU, containing vorolanib (2.7 mg), failed to meet a key late-stage endpoint in the LUGANO trial against on-label 2 mg aflibercept, EYLEA.
However, EyePoint emphasized the drug's strong safety profile, solid secondary results, and the potential for approval if a second Phase III study proves positive. In LUGANO, the primary non-inferiority endpoint in the full intent-to-treat population was not met, primarily due to an unusually strong control arm. Despite this, DURAVYU demonstrated strong anatomic control, a more than 40% reduction in treatment burden, and no significant safety concerns compared to the control arm.
The company expects top-line data from the LUCIA trial, another Phase III wet AMD study, in the fourth quarter of 2024. If successful, EyePoint plans to file an NDA in the first half of 2027. Additionally, two fully enrolled Phase III diabetic macular edema studies, COMO and CAPRI, with expected data in the fourth quarter of 2027, further bolster the company's pipeline.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
